DiaMedica Therapeutics, Inc. (DMAC) vs Relmada Therapeutics, Inc. (RLMD)

DiaMedica Therapeutics, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Relmada Therapeutics, Inc. are of similar size ($422.2M and $406.4M). Across the 8 metrics below, Relmada Therapeutics, Inc. leads on 6 and DiaMedica Therapeutics, Inc. on 2.

Valuation

Metric DMAC RLMD Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 11.16 2.08 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield (9.07%) (23.50%) (28.84%)
Free cash flow yield (7.37%) (29.59%) (23.03%)

Profitability

Metric DMAC RLMD Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (114.62%) (55.66%) (57.72%)
Return on assets (98.18%) (51.57%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMAC RLMD Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (16.67%) 45.28% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC RLMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 29.52 4.73
Net debt to EBITDA 1.70 1.57 0.96

Dividend

Metric DMAC RLMD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DMAC RLMD Biotechnology median
Market cap 422.24m 406.41m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack